Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
about
Large animal models of cardiovascular diseaseAnimal models of diabetic macrovascular complications: key players in the development of new therapeutic approachesInsulin and glucose play a role in foam cell formation and function.CD40 ligand promotes Mac-1 expression, leukocyte recruitment, and neointima formation after vascular injury.Smooth muscle progenitor cells: friend or foe in vascular disease?The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model.Transcriptional Control of Vascular Smooth Muscle Cell Proliferation by Peroxisome Proliferator-Activated Receptor-gamma: Therapeutic Implications for Cardiovascular Diseases.Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.PPARγ modulates vascular smooth muscle cell phenotype via a protein kinase G-dependent pathway and reduces neointimal hyperplasia after vascular injury.Effects of rosiglitazone on contralateral iliac artery after vascular injury in hypercholesterolemic rabbits.Oleic acid activates MMPs up-regulation through SIRT1/PPAR-γ inhibition: a probable linkage between obesity and coronary arterial disease.Lysophosphatidic acid-induced vascular neointimal formation in mouse carotid arteries is mediated by the matricellular protein CCN1/Cyr61.Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formationAttenuation of accumulation of neointimal lipid by pioglitazone in mice genetically deficient in insulin receptor substrate-2 and apolipoprotein E.Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects.Pioglitazone Attenuates Injury-Induced Neointima Formation in Mouse Femoral Artery Partially through the Activation of AMP-Activated Protein Kinase.PPAR attenuates intimal hyperplasia by inhibiting TLR4-mediated inflammation in vascular smooth muscle cells
P2860
Q26766350-49641C7C-5AB4-45C3-8A4E-1F90BB84C3F4Q26822630-867F25A8-60E7-4867-84E8-5306BA5B6ED4Q30440798-443D21E5-4A24-4CCC-AE02-372C24BD314AQ30441065-AE89813F-33B0-4F30-9B82-4A2034815607Q35237562-D6799B90-E95F-42A7-A199-09D9BA18158BQ36367490-21BCA7F5-E31E-4F47-9677-B6F5A42D0AE5Q36426782-DE919A55-A271-4494-988E-1FF78E7AA74FQ36578665-7F1FE480-534D-49D2-9E65-A2B4F9040F36Q37072778-2CAA2991-1DE5-4851-87F7-F4142ACD4748Q37361545-EEDD27D4-97CB-472C-99B9-909936DDA865Q38623544-881DE734-800C-4357-BE58-8730DEF6E692Q38778704-89E569C8-05A8-42EF-9A17-BEF7134CBD0AQ39269910-C20EA002-11A1-49E7-BD28-20E3BC7867E4Q41932068-671A079D-D1E4-4926-9ADE-FD28B8D32138Q46472652-ED38CFEA-20CD-4E36-A2B1-364297C69A01Q49423096-4E2999F7-181D-430C-8805-0C374C67F750Q51014952-E1200640-FDB7-4C8D-AFAA-F3CEDB7A83F8Q57892049-CC960CFC-D2AF-453A-9701-E39332A1E2E8
P2860
Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Rosiglitazone reduces the acce ...... jury model of type 2 diabetes.
@ast
Rosiglitazone reduces the acce ...... jury model of type 2 diabetes.
@en
type
label
Rosiglitazone reduces the acce ...... jury model of type 2 diabetes.
@ast
Rosiglitazone reduces the acce ...... jury model of type 2 diabetes.
@en
prefLabel
Rosiglitazone reduces the acce ...... jury model of type 2 diabetes.
@ast
Rosiglitazone reduces the acce ...... jury model of type 2 diabetes.
@en
P2093
P1433
P1476
Rosiglitazone reduces the acce ...... jury model of type 2 diabetes.
@en
P2093
Ann C Czarnik
Ian J Sarembock
J William Phillips
Jerry Nadler
John M Sanders
Kurt G Barringhaus
Zandong Yang
P304
P356
10.1161/01.CIR.0000092886.52404.50
P407
P577
2003-09-29T00:00:00Z